{
    "clinical_study": {
        "@rank": "14878", 
        "acronym": "PETRA", 
        "arm_group": {
            "arm_group_label": "111In-Pertuzumab + SPECT-CT", 
            "arm_group_type": "Experimental", 
            "description": "Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging."
        }, 
        "brief_summary": {
            "textblock": "The general objective of the study is to improve the care of women with Human Epidermal\n      Growth Factor Receptor-2 (HER2) positive metastatic breast cancer by using a radio-labelled\n      biomarker with whole body Single Photon Emission Computed Tomography (SPECT) imaging to\n      predict who will respond to treatment with Trastuzumab."
        }, 
        "brief_title": "Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC)", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Metastatic or locally recurrent adenocarcinoma of the breast (local recurrence not\n             amenable to surgical resection of curative intent)\n\n          2. Tumour HER2 positive by immunohistochemistry for HER2 protein over-expression or by\n             Fluorescence in situ Hybridization (FISH) for HER2 gene amplification, as defined by\n             American Society of Clinical Oncology/College of American Pathologists guidelines\n\n          3. Initiating treatment with TmAb\n\n          4. Clinically measurable disease by RECIST\n\n        Exclusion Criteria:\n\n          1. Male gender.\n\n          2. Less than 18 years of age.\n\n          3. Life expectancy < 12 weeks.\n\n          4. Only site of metastases is liver.\n\n          5. Eastern Cooperative Oncology Group (ECOG) performance status of > 2.\n\n          6. Currently receiving PmAb or lapatinib for treatment of MBC.\n\n          7. Having received TmAb as adjuvant therapy within the previous 12 months.\n\n          8. Required to receive another radiopharmaceutical during the first week of the study.\n\n          9. Hypersensitivity to monoclonal antibodies.\n\n         10. Left Ventricular Ejection Fraction (LVEF) < 50% at baseline (within 42 days of study\n             registration) as determined by either echocardiogram (ECHO) or Multi-Gated\n             Acquisition (MUGA) scan.\n\n         11. Hematology and/or biochemistry parameters outside acceptable ranges:\n\n               -  absolute neutrophil count <1,500 cells/mm3,\n\n               -  platelet count <100,000 cells/mm3,\n\n               -  hemoglobin <9 g/dL,\n\n               -  total bilirubin > upper limit of normal (ULN) (unless subject has documented\n                  Gilbert's Syndrome),\n\n               -  aspartate aminotransferase (AST) [serum glutamic oxaloacetic transaminase(SGOT)]\n                  and alanine aminotransferase (ALT) [serum glutamic pyruvate transaminase(SGPT)]\n                  >2.5 \u00d7 ULN,\n\n               -  serum creatinine >2.0 mg/dL or 177 \u03bcmol/L,\n\n               -  alanine aminotransferase (ALP) >2.5 x ULN.\n\n         12. Known pregnancy or lactating female (e.g. positive serum beta-human chorionic\n             gonadotropin (B-hCG) pregnancy test).\n\n         13. For women of childbearing potential, failure to agree to use a highly effective form\n             of contraception (patient and/or partner, e.g., surgical sterilization) or two\n             effective forms of contraception (a reliable barrier method in conjunction with\n             spermicidal jelly, birth control pills, or contraceptive hormone implants) and to\n             continue its use for the duration of study treatment.\n\n         14. Any condition, which in the investigator's opinion would not make the patient a\n             suitable candidate for inclusion in the trial.\n\n         15. Participation in another clinical trial.\n\n         16. Inability to provide informed consent."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805908", 
            "org_study_id": "OCOG-2011-PETRA"
        }, 
        "intervention": {
            "arm_group_label": "111In-Pertuzumab + SPECT-CT", 
            "description": "111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.", 
            "intervention_name": "111In-Pertuzumab + SPECT-CT", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metastatic", 
            "breast cancer", 
            "herceptin", 
            "imaging", 
            "tumour response", 
            "adenocarcinoma", 
            "SPECT-CT", 
            "pertuzumab", 
            "trastuzumab"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Juravinski Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Som Mukherjee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Odette Sunnybrook Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Kathleen Pritchard", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "clinek@mcmaster.ca", 
            "last_name": "Kathryn Cline", 
            "phone": "905-527-2299", 
            "phone_ext": "42650"
        }, 
        "overall_official": [
            {
                "affiliation": "Ontario Clinical Oncology Group, McMaster University", 
                "last_name": "Mark Levine", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Toronto", 
                "last_name": "Raymond Reilly", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ontario Clinical Oncology Group (OCOG)", 
                "last_name": "Kathleen Pritchard", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 8 (Day 8 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.", 
                "measure": "Change in tumour SUV (Standardized Uptake Value) from baseline to Day 8.", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "The safety, i.e. toxicities, attributable to 111In-Pertuzumab injections will be evaluated using the National Cancer Institute (NCI) Common Termination for Adverse Events Version 4.", 
                "measure": "Safety attributable to 111In-Pertuzumab injections", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805908"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The pharmacokinetics of 111In-PmAb and tumour and normal tissue localization properties of 111In-PmAb will be measured. Standard PK parameters (t1/2 alpha, t1/2\u03b2, V1, Vss and CL) will be calculated.", 
                "measure": "Pharmacokinetics (PK) and tumour and normal tissue localization properties of 111In-PmAb will be measured.", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "The dose of 111In-PmAb that is associated with the optimal SPECT-CT images will be established.", 
                "measure": "Optimal mass dose of 111In-PmAb", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 36 (Day 36 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.", 
                "measure": "Change in tumour SUV from Baseline to Day 36", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria.", 
                "measure": "Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria.", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Ontario Clinical Oncology Group (OCOG)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ontario Clinical Oncology Group (OCOG)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}